FDA Brief

Warning letters Drugs

FDA warning letter to

Curia New York, Inc.

High riskIssued Sep 18Posted Sep 29Center for Drug Evaluation and Research (CDER)

FDA warned Curia New York's Rensselaer, New York API plant that undocumented lab injections, shredded records and shared passwords violate CGMP.

What happened

FDA inspected Curia New York's active pharmaceutical ingredient (API) plant in Rensselaer, New York, from January 28 to February 5, 2026. Investigators found thousands of unexplained trial injections in Empower and TotalChrom chromatography data, original lab printouts and signed review checklists in shred bins, and analysts using a colleague's login credentials. FDA reviewed Curia's February 27, 2026 response to the Form FDA 483 (the list of observations given at the end of an inspection) and called it inadequate.

What FDA found

  1. Laboratory records did not include all test data: analysts ran thousands of undocumented trial injections on HPLC and UPLC systems, nearly 20 percent of Empower trial injections in a 'Developer' role rather than an 'Operator' role.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  2. The quality unit did not control records: original pH meter and analytical balance printouts and reviewer-signed data review checklists were found in laboratory shred bins, and the firm could not tie them to any batch or person.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  3. The quality unit's review of the shred bins did not cover all bins found during the inspection, and one identified bin was left out of the summary report with no explanation.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  4. Laboratory staff reviewed photocopies of notebook pages instead of the original data and signed the original analyst notebooks without verifying changes, contrary to the firm's own procedure.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  5. Analysts shared usernames and passwords on the computerized GMP system, and one analyst used another analyst's credentials to run calibrations and sample testing.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)

What FDA wants

Curia must send a written response to CDER within 15 business days, identifying FEI 1310298 and ATTN: Compliance Officer Sneha Patel. FDA wants independent investigations of the trial injections and shred bin contents, data-integrity assessments covering all computerized systems at all facilities, a risk assessment, a global corrective action plan, and confirmation that a data integrity compliance officer will be hired.

Who should pay attention

  • drug manufacturers that buy APIs from this Rensselaer facility
  • quality teams relying on Curia certificates of analysis and batch records
  • firms with pending or planned applications listing this site as a manufacturer

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk